Consino was approved by the company's IPO, the first A-H vaccine stock was born!

Guide: Consinibolo Bio was listed on the Hong Kong Stock Exchange in March 2019 !----, and on July 15, the CSRC issued a number of IPO approvals for corporate companies, including Consino BioConsinctbios was listed on the Hong Kong Stock Exchange in March 2019, meaning that if it goes public, it will become the first A-share "A-H" vaccine stockOn July 15th, Consino Bio issued an initial public offering of shares and listed on the company's prospectus, which accounted for no more than 24.8 million shares, or 10.02 percent of the company's total share capital after the A-share issueIt is understood that, as the vaccine products have not yet been commercialized, in the reporting period did not achieve profitability, Consino Bio's IPO adopted the fifth set of listing standardsAccording to the prospectus, in the first quarter ended March 31, 2020, Considine Bio achieved revenue of RMB4.03 million, up 605.1% YoY, and the net loss attributable to shareholders of the parent company was RMB23.103 million, down 48.94% YoYFounded in 2009, Consineo Bio is dedicated to the development, production and marketing of vaccine products, and currently has 16 innovative vaccine products, including 13 indications for the prevention of Ebola virus disease, meningitis, new crown pneumonia, baibaio, tuberculosis, and 19 licensed invention patentsIn recent times, Considine Bio has gained notoriety for its leading position in the development of new vaccines worldwideIn mid-March, the recombinant new coronavirus vaccine (Ad5-nCoV), developed jointly by the Institute of Bioengineering at the Institute of Military Medicine of the Conseh NoOn May 22, the Lancet, an international authoritative medical journal, published the results of clinical data on human trials of the Ad5-nCoV vaccine online, showing that all 108 clinical volunteers in the first phase had significant cellular immune responsesThis is the world's first new crown vaccine human clinical dataOn June 11, the vaccine completed Phase II clinical trialsThe new crown vaccine industrialization base of Consino Bio is under construction and the future production capacity is expected to be no less than 200 million dosesThe prospectus revealed that the 1 billion yuan raised is intended for the expansion of new vaccine production capacity and research and development of new vaccine products, of which 550 million yuan will be used for the second phase of the production base construction, 150 million yuan will be used for vaccine research and development, 50 million yuan will be used for vaccine traceability, cold chain logistics system and information system construction, and another 250 million yuan will be used as supplementary liquidity